MX394121B - Anticuerpos que se unen a cd39 y sus usos - Google Patents

Anticuerpos que se unen a cd39 y sus usos

Info

Publication number
MX394121B
MX394121B MX2021015518A MX2021015518A MX394121B MX 394121 B MX394121 B MX 394121B MX 2021015518 A MX2021015518 A MX 2021015518A MX 2021015518 A MX2021015518 A MX 2021015518A MX 394121 B MX394121 B MX 394121B
Authority
MX
Mexico
Prior art keywords
antibodies
bind
present disclosure
antigen binding
disclosure relates
Prior art date
Application number
MX2021015518A
Other languages
English (en)
Other versions
MX2021015518A (es
Inventor
Andrew Lake
Austin Dulak
Bianka Prinz
Erik Devereaux
Matthew Rausch
Michael Warren
Nels P Nielson
Pamela M Holland
Scott Chapel
Sonia Das
Tauqeer Zaidi
Original Assignee
Surface Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Oncology Inc filed Critical Surface Oncology Inc
Publication of MX2021015518A publication Critical patent/MX2021015518A/es
Publication of MX394121B publication Critical patent/MX394121B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-CD39, y porciones de unión al antígeno de estos y su uso en el tratamiento del cáncer.
MX2021015518A 2018-03-14 2019-03-13 Anticuerpos que se unen a cd39 y sus usos MX394121B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862642938P 2018-03-14 2018-03-14
US201962803235P 2019-02-08 2019-02-08
PCT/US2019/022108 WO2019178269A2 (en) 2018-03-14 2019-03-13 Antibodies that bind cd39 and uses thereof

Publications (2)

Publication Number Publication Date
MX2021015518A MX2021015518A (es) 2022-07-21
MX394121B true MX394121B (es) 2025-03-24

Family

ID=67903871

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021015518A MX394121B (es) 2018-03-14 2019-03-13 Anticuerpos que se unen a cd39 y sus usos
MX2020009568A MX391028B (es) 2018-03-14 2019-03-13 Anticuerpos que se unen a cd39 y sus usos
MX2022003718A MX2022003718A (es) 2018-03-14 2020-09-14 Anticuerpos que se unen a cd39 y sus usos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020009568A MX391028B (es) 2018-03-14 2019-03-13 Anticuerpos que se unen a cd39 y sus usos
MX2022003718A MX2022003718A (es) 2018-03-14 2020-09-14 Anticuerpos que se unen a cd39 y sus usos.

Country Status (14)

Country Link
US (4) US10738128B2 (es)
EP (2) EP3765524A4 (es)
JP (3) JP7037218B2 (es)
KR (4) KR102411490B1 (es)
CN (2) CN113754768B (es)
AU (3) AU2019235842B2 (es)
BR (2) BR122022000386B1 (es)
CA (1) CA3092635A1 (es)
IL (3) IL301295A (es)
MA (1) MA52022A (es)
MX (3) MX394121B (es)
NZ (2) NZ767596A (es)
SG (1) SG11202008390SA (es)
WO (1) WO2019178269A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
IL316357A (en) 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SG11202002195YA (en) * 2017-11-15 2020-04-29 Innate Pharma Potentiating the effect of atp release
MX394121B (es) 2018-03-14 2025-03-24 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos
US20230242660A1 (en) * 2019-02-21 2023-08-03 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
US20220372160A1 (en) 2019-09-16 2022-11-24 Surface Oncology, Inc. Anti-CD39 Antibody Compositions and Methods
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
CN114651013B (zh) * 2019-11-05 2025-03-14 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
CN113372444A (zh) * 2020-03-09 2021-09-10 北京恩瑞尼生物科技股份有限公司 通过抑制胞外核苷酸酶和抗体-介导靶向吞噬预防或逆转t-细胞衰竭的组合物与用途
US20230416394A1 (en) * 2020-11-27 2023-12-28 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta
US12577299B2 (en) 2021-05-07 2026-03-17 Surface Oncology, LLC Anti-IL-27 antibodies and uses thereof
US20250011455A1 (en) * 2021-05-12 2025-01-09 Hangzhou Bangshun Pharmaceutical Co., Ltd. ANTI-CD39 Antibody, Preparation Method Therefor And Use Thereof
TW202307006A (zh) * 2021-06-03 2023-02-16 美商表面腫瘤學公司 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
WO2023164872A1 (en) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
WO2023165561A1 (en) 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anti-cd39 antibodies and use thereof
US20250228938A1 (en) * 2022-03-08 2025-07-17 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
WO2024109585A1 (zh) * 2022-11-23 2024-05-30 广东菲鹏制药股份有限公司 抗cd39抗体及其应用
AU2023402712A1 (en) 2022-12-01 2025-05-08 Innate Pharma Compositions and methods for neoadjuvant treatment in cancer comprising anti-cd39 antibodies
WO2024229461A2 (en) 2023-05-04 2024-11-07 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
KR102931343B1 (ko) 2023-08-10 2026-02-25 현대자동차주식회사 유니버설 구동 장치
KR102950060B1 (ko) 2023-09-18 2026-04-07 현대자동차주식회사 링키지 구조 및 이를 이용한 유니버설 구동장치
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025233266A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd39 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2026055167A1 (en) 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2002361763A1 (en) 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
DK3153526T3 (da) * 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
HRP20150766T1 (hr) 2009-03-20 2015-08-14 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Oksidirani derivati triazolilpurina, korisni kao ligandi adenozinskog receptora a2a, te namijenjeni upotrebi kao medikamenti
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
SI2531492T1 (sl) 2010-02-05 2016-08-31 Heptares Therapeutics Limited Derivati 1,2,4-triazin-4-amina
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
CN105153307A (zh) 2010-05-04 2015-12-16 梅里麦克制药股份有限公司 抗表皮生长因子受体(egfr)的抗体及其用途
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
BR112016015140A2 (pt) 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
WO2016073845A1 (en) * 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
EP3218407A1 (en) 2014-11-11 2017-09-20 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
CA3197849A1 (en) 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
SI3334431T1 (sl) 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US20190071514A1 (en) * 2016-03-14 2019-03-07 Innate Pharma Anti-cd39 antibodies
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
IL316357A (en) * 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MX394121B (es) 2018-03-14 2025-03-24 Surface Oncology Inc Anticuerpos que se unen a cd39 y sus usos
US20230242660A1 (en) * 2019-02-21 2023-08-03 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies

Also Published As

Publication number Publication date
KR20230020023A (ko) 2023-02-09
JP7068736B2 (ja) 2022-05-17
EP3765524A2 (en) 2021-01-20
NZ767596A (en) 2022-01-28
IL287565B2 (en) 2023-08-01
BR112020018480A2 (pt) 2020-12-22
MX391028B (es) 2025-03-21
MA52022A (fr) 2021-01-20
IL277242B1 (en) 2023-03-01
BR122022000386B1 (pt) 2022-09-27
WO2019178269A3 (en) 2019-10-17
IL277242A (en) 2020-10-29
KR102411490B1 (ko) 2022-06-22
CA3092635A1 (en) 2019-09-19
CN112262155A (zh) 2021-01-22
JP2021518103A (ja) 2021-08-02
NZ782442A (en) 2022-01-28
MX2022003718A (es) 2022-04-26
JP7037218B2 (ja) 2022-03-16
AU2019235842B2 (en) 2022-02-03
EP3765524A4 (en) 2021-12-22
WO2019178269A2 (en) 2019-09-19
KR102495666B1 (ko) 2023-02-06
JP2022020862A (ja) 2022-02-01
EP4043496A1 (en) 2022-08-17
KR20200131272A (ko) 2020-11-23
KR102411489B1 (ko) 2022-06-23
MX2020009568A (es) 2022-03-28
US20190284295A1 (en) 2019-09-19
IL301295A (en) 2023-05-01
US20200399394A1 (en) 2020-12-24
KR20210143933A (ko) 2021-11-29
IL287565B1 (en) 2023-04-01
IL277242B2 (en) 2023-07-01
US20200277394A1 (en) 2020-09-03
SG11202008390SA (en) 2020-09-29
US20210363268A1 (en) 2021-11-25
CN113754768B (zh) 2023-01-06
AU2019235842A1 (en) 2020-09-24
US10738128B2 (en) 2020-08-11
MX2021015518A (es) 2022-07-21
JP2022115879A (ja) 2022-08-09
AU2022202656A1 (en) 2022-05-12
AU2021269448A1 (en) 2022-01-06
BR112020018480B1 (pt) 2022-09-27
CN113754768A (zh) 2021-12-07
KR20220088802A (ko) 2022-06-28
US10793637B2 (en) 2020-10-06
AU2021269448B2 (en) 2022-02-03
IL287565A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
MX394121B (es) Anticuerpos que se unen a cd39 y sus usos
CR20190550A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MX2019014318A (es) Proteinas de union a nectina-4 y metodos de uso de las mismas.
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2020000960A (es) Anticuerpos anti-tigit.
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CU20170169A7 (es) Anticuerpos de factor xi
MX2018005550A (es) Anticuerpos que se unen especificamente a tim-3 y sus usos.
CL2018000431A1 (es) Anticuerpos anti-bcma, moléculas de unión de antígeno específicas que vinculan bcma y cd3, y sus usos relacionados.
CR20150522A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA TNFa
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
MX2016009961A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
CR20150575A (es) Anticuerpos humanos pac1
UY35478A (es) PROTEÍNAS DE UNIÓN ESPECÍFICAS DUALES DIRIGIDAS CONTRA IL-1ß y/o IL-17
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.